O NE OF THE characteristic symptoms of premenstrual dysphoric disorder (PMDD) is sleep disturbance before menstruation, mainly involving hypersomnia, and insomnia can occur in some cases. In most PMDD patients, the administration of selective serotonin reuptake inhibitors (SSRI) leads to rapid resolution of symptoms such as depressed mood, anxiety, and affective lability. However, premenstrual sleep disturbances, such as hypersomnia and insomnia, may persist. I encountered a case in which ramelteon was effective for the treatment of residual sleep disturbances (hypersomnia) that persisted in a patient with PMDD even after SSRI therapy. Herein, I present my experience with this patient.
The patient was a 29-year-old woman with a 4-year history of PMDD and no physical complications. Her menstrual cycle was 28 days in length. For 10 days before menstruation, she experienced symptoms such as marked affective lability, marked irritability and anger, marked depressed mood, marked anxiety and tension, decreased interest in usual activities, lethargy, marked lack of energy, cravings for sweet foods, excessive daytime sleepiness, and frequent nocturnal awakenings. Although most of her premenstrual symptoms showed resolution with an intermittent dosing regimen of escitalopram at 20 mg/day, the excessive daytime sleepiness and frequent nocturnal awakenings persisted from days 7 to 1 before menstruation began, disrupting her daily activities during this period. She expressed a strong desire for improvement in these premenstrual sleep problems. With the aim of ameliorating the frequent nocturnal awakenings, ramelteon was additionally administered at a dose of 8 mg/day at bedtime during the luteal phase only, which resulted in complete resolution of not only the frequent nocturnal awakenings, but also the excessive daytime sleepiness during her subsequent menstrual cycle. She gave informed consent for the publication of this description, and her anonymity has been preserved.
I experienced a case of PMDD that responded favorably to additional administration of ramelteon. Many patients with PMDD experience premenstrual hypersomnia and insomnia, and they often do not respond adequately to SSRI. Ramelteon is a selective melatonin MT1/MT2 receptor agonist. Some studies have shown that melatonin function is lower during the luteal phase in patients with PMDD than during the follicular phase in patients with PMDD or during the luteal phase in healthy women.
1,2 As a melatonin receptor agonist, ramelteon compensated for the decrease in melatonin function during the luteal phase in the present patient with PMDD, ameliorating both her frequent nocturnal awakenings and excessive daytime sleepiness. Although the symptoms of PMDD are thought to be associated with abnormal functioning of the serotonergic system, my experience suggests that melatonin may also play a role in sleep-related symptoms such as hypersomnia and insomnia.
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Psychosis with suicide attempt in Sneddon syndrome doi:10.1111/pcn.12489 S NEDDON SYNDROME IS a rare, non-inflammatory thrombotic vasculopathy affecting the cerebrovascular and dermatologic systems, and presenting with recurrent strokes and livedo reticularis. 1 The annual incidence of Sneddon syndrome is approximately four per 1 million population, and generally occurs in women aged 20-42 years. 2 To our knowledge, this is the first case of Sneddon syndromerelated psychotic symptoms leading to a suicide attempt, although a previous study by Lalanne et al. reported a case of a suicide attempt in the context of bipolar symptoms related to Sneddon syndrome. 2 The symptom in our patient persisted for weeks, although there was no evidence of the Sneddon syndrome progressing, and eventually subsided after the patient was administered a relatively low dose of antipsychotics.
A 44-year-old female patient with idiopathic Sneddon syndrome 3 with sequelae of deafness and multiple cerebral infarctions was admitted for a suicide attempt because of a voice-commanding auditory hallucination directing her to drink bleached water. She presented with a history of attempting suicide because of a similar occurrence at age 43 characterized by a voice-commanding auditory hallucination and subsequent cuts to her wrist. She had denied suffering from a depressive mood at that time and was regularly followed up at clinics. The patient had no family history of psychiatric disorder.
After admission, an initial treatment of oral haloperidol (1 mg/day) was administered, rather than second-generation antipsychotics (which are associated with tendency of metabolic syndrome and increased risk of stroke), along with a physical work-up to test for possible organic etiology. The auditory hallucination was still noted and haloperidol was increased to 5 mg/day. A brain magnetic resonance imaging (MRI) scan revealed no evidence of an interval change or new intracranial lesions, compared with MRI scans performed 2 years prior. Functional MRI (fMRI) was not performed, so we failed to specify the relation between clinical hallucinations and fMRI modifications. The complete blood cells, electrolyte levels, and renal and liver function were normal. The antiphospholipid, lupus anticoagulant, IgG immunoglobulin, and anti-nuclear-and anti-double-stranded DNA autoantibodies were also all within the normal range. During her hospital stay, the patient's psychotic symptoms gradually improved on haloperidol (5 mg/day); for progressive extrapyramidal symptoms, haloperidol was replaced with chlorpromazine (25 mg/day) after discharge a few weeks later, with a fair response. No exacerbation of the psychosis was noted during follow-ups over the next 3 years at our clinic.
In our patient, idiopathic Sneddon syndrome was diagnosed. 3 She had deafness and MRI showed multiple cerebral infarctions. The livedo reticularis was noted over her four limbs and the skin biopsy revealed thrombosis of subcutaneous arterioles. Systemic lupus erythematosus, polyarteritis nodosa, cryoglobulinemia, livedoid vasculitis, cold agglutinin disease, arteriosclerosis, and others were all excluded.
1 During this hospitalization, her autoimmune factors were normal and Sneddon syndrome was still considered. Her psychotic symptoms were fully remitted under a low dose of antipsychotics (haloperidol at 5 mg/day in the ward, and subsequent chlorpromazine at 25 mg/day in the clinic), without recurrence of psychosis over the following 3 years.
There may be some debate about whether the patient's symptoms indicated a comorbid primary psychosis or were secondary to Sneddon syndrome. However, the evidence suggests that this is not a comorbid primary psychosis, because of the absence of a family history of psychiatric disorder, the relatively late onset of the psychotic symptoms, and a lack of concomitant delusions.
We hypothesize that the psychotic symptoms were secondary to Sneddon syndrome. Suicide risk should be considered in cases where Sneddon syndrome is the diagnosis; a low dose of antipsychotics may be effective for controlling the symptoms and preventing side-effects.
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